Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Although chronic myelogenous leukemia (CML) is effectively controlled by Bcr-Abl kinase inhibitors, resistance to inhibitors, progressive disease, and incomplete eradication of Bcr-Abl–expressing cells are concerns for the long-term control and suppression of this disease. We describe a novel approach to targeting key proteins in CML cells with a ubiquitin-cycle inhibitor, WP1130. Bcr-Abl is rapidly modified with K63-linked ubiquitin polymers in WP1130-treated CML cells, resulting in its accumulation in aggresomes, where is it unable to conduct signal transduction. Induction of apoptosis because of aggresomal compartmentalization of Bcr-Abl was observed in both imatinib-sensitive and -resistant cells. WP1130, but not Bcr-Abl kinase inhibitors, directly inhibits Usp9x deubiquitinase activity, resulting in the down-regulation of the prosurvival protein Mcl-1 and facilitating apoptosis. These results demonstrate that ubiquitin-cycle inhibition represents a novel and effective approach to blocking Bcr-Abl kinase signaling and reducing Mcl-1 levels to engage CML cell apoptosis. This approach may be a therapeutic option for kinase inhibitor–resistant CML patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationThe emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Targeting proteins for degradation.
Schrader, E. K., Harstad, K. G., & Matouschek, A. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.250 · Cited by 287
Cited by
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Deubiquitinases in cancer: new functions and therapeutic options
Fraile, J. M., Quesada, V, Rodríguez, D., Freije, J. M. P., & López-Otín, C. (2012) · Oncogene · doi:10.1038/onc.2011.443 · Cited by 453
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma
Initiative, A. P. C. G., Pérez-Mancera, P. A., Rust, A. G., van der Weyden, L., Kristiansen, G., Li, A., Sarver, A. L., Silverstein, K. A. T., Grützmann, R., Aust, D., et al. (2012) · Nature · doi:10.1038/nature11114 · Cited by 316
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Metadata
- Authors
- Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G., Talpaz, M., & Donato, N. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-03-17
- Volume
- 117
- Issue
- 11
- Pages
- 3151-3162
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1972196873
- Cited by
- 112
- References
- 5
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. https://app.cochat.ai/papers/10.1182/blood-2010-03-276477
- The paper
- Sun, H., Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Bartholomeusz, G., Talpaz, M., & Donato, N. J. (2011). Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. https://doi.org/10.1182/blood-2010-03-276477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.